secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001104659-22-126446
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics enters $25M common stock purchase agreement with Lincoln Park Capital
--------------------------------------------------------------------------------

- Up to $25M in common stock may be sold to Lincoln Park over 24 months at Marker's discretion.
- Pricing based on prevailing market prices; no upper limit per share and no warrants issued.
- Marker issued 1,804,098 commitment shares to Lincoln Park as consideration.
- Lincoln Park covenants not to engage in short selling or hedging of Marker's stock.
- Proceeds to fund Phase 2 ARTEMIS trial, lymphoma/pancreatic programs, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/0001104659-22-126446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/tm2232522d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer